Cardiopulmonary Disease Diagnostics and Treatment Market Research Report – Forecast to 2027

Cardiopulmonary Disease Diagnostics and Treatment Market: Disease Type (Cardiovascular and Respiratory Diseases), Type (Diagnosis-Electrocardiogram and Treatment -Medication), End-Users (Hospitals, Diagnostic Centers) --Global Forecast Till 2027

ID: MRFR/Pharma/4929-HCR | | Region: Global | 85 pages

Cardiopulmonary Disease Diagnostics and Treatment Market Scenario


The cardiopulmonary disease is used to describe a wide range of series of disorders which affect the heart and the lungs. Cardiovascular disease is a universal term for conditions affecting the heart or blood vessels. It's usually related with a build-up of fatty deposits inside the arteries known as atherosclerosis. It can also be related with an injury to arteries in organs such as the brain, kidney, and heart. Respiratory disease is a medical term that includes extreme conditions affecting the organs and tissues which make gas exchange possible in higher organisms. Respiratory diseases range from mild to self-limiting, such as the common cold, to life-threatening entities like bacterial pneumonia, pulmonary embolism, and lung cancer.


Treatment options vary depending on the type of cardiopulmonary disease present and may include changes in diet or lifestyle, use of medications issued on prescription or surgery. The most common cardiopulmonary diseases are hypertension, stroke, and coronary heart disease. Untreated, cardiopulmonary diseases can be deadly. Cardiopulmonary diseases are the major cause of death globally.


The substantial growth in the frequency of health conditions related to the lungs and heart is the key factor to boosts the growth of this market. Also, the increase in aged population and the rising frequency in cardiovascular and respiratory diseases is also anticipated to drive the global market over the forecast period. Exposure to nicotine, tobacco products, and others increases the risk of obtaining cardiopulmonary diseases.


Increase in the rise of advanced technological equipment’s for diagnosing the disease will drive market rate exponentially. However, the huge cost of treatment and the regulatory nature of government on pharmaceutical companies will hamper the growth of the market.


Segmentation


The cardiopulmonary disease diagnostics and treatment market has been segmented on the basis of disease type, type, and end-user.


On the basis of disease type, the market has been classified as cardiovascular and respiratory diseases. The cardiovascular diseases are segmented into coronary artery disease, angina pectoris, myocardial infarction, dysrhythmia, hypertension, and others. The respiratory diseases are segmented into influenza, asthma, bronchitis, emphysema, cystic fibrosis, and others.


On the basis of type, the market has been classified as diagnosis and treatment. The diagnosis market is segmented into an electrocardiogram (ECG), Holter monitoring, echocardiogram, stress test, cardiac catheterization, cardiac computerized tomography (CT) scan, cardiac magnetic resonance imaging (MRI), single-photon emission computed tomography (SPECT), stress blood pressure monitors, pulse oximeters and spirometry. The treatment market is segmented into medications. The medications segment is further sub-segmented into angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBS), anticoagulants, antiplatelet agents and others.


On the basis of end users, the market has been classified as hospitals, clinics, diagnostic centers, specialty clinics and rehab centers, research institutes and others.


On the basis of region, the market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas has been further segmented into North America and South America, with the North American market divided into the US and Canada.


The European cardiopulmonary disease diagnostics and treatment market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 


The cardiopulmonary disease diagnostics and treatment market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The cardiopulmonary disease diagnostics and treatment market in the Middle East and Africa has been segmented into the Middle East and Africa.


Regional Market Summary


Cardiopulmonary Disease Diagnostics and Treatment Market Share, by Region, 2017 (%)


Cardiopulmonary Disease Diagnostics and Treatment


Source: MRFR Analysis


In the cardiopulmonary disease diagnostics and treatment market, North America is anticipated to account for the largest market share due to the early adoption of advanced medical technologies, the rise in awareness, the rise in growth of the healthcare sector, and due to favorable compensation setting for many surgical procedures.


The European market is expected to hold the second largest market share. The market growth in this region can be attributed to rising frequency of cardiovascular disorders, increasing number of surgeries and increasing demand for advanced treatment procedures are boosting the European market.


The market share in Asia-Pacific is also projected to experience growth in the near future due to access to optimal treatment facilities and growing demand for advanced technology, better adoption rate, increase in disposable income, and rising medical tourism.


The market in the Middle East and Africa is expected to account for the smallest share of the cardiopulmonary disease diagnostics and treatment market due to an underdeveloped healthcare sector, lack of technical knowledge, and poor medical facilities.


Key Players


Some of the key players in the cardiopulmonary disease diagnostics and treatment market are Cardinal Health, Cosmed Medical, GE Healthcare, Halma plc, Hill-Rom Holdings, Inc., Koninklijke Philips N.V., MGC Diagnostics Corporation, NIHON KOHDEN CORPORATION, Schiller AG, Masimo Corporation, and Vyaire Medical Inc.


Cardiopulmonary Disease Diagnostics and Treatment Market, by Disease Type


Cardiovascular diseases



  • Coronary artery disease

  • Angina pectoris

  • Myocardial infarction

  • Dysrhythmia

  • Hypertension

  • Others


Respiratory diseases



  • Influenza

  • Asthma

  • Bronchitis

  • Emphysema

  • Cystic fibrosis

  • Others


Cardiopulmonary Disease Diagnostics and Treatment Market, by Type


Diagnostics



  • Electrocardiogram (ECG)

  • Holter monitoring

  • Echocardiogram

  • Stress test

  • Cardiac catheterization

  • Cardiac computerized tomography (CT) scan

  • Cardiac magnetic resonance imaging (MRI)

  • Single-photon emission computed tomography (SPECT)

  • Stress blood pressure monitors

  • Pulse oximeters

  • Spirometry


Treatment



  • Medication

  • Angiotensin-converting enzyme (ACE) inhibitors

  • Angiotensin II receptor blockers (ARBS)

  • Anticoagulants

  • Antiplatelet agents

  • Others


Cardiopulmonary Disease Diagnostics and Treatment Market, by End-User



  • Hospitals

  • Clinics

  • Diagnostic centers

  • Specialty Clinics and Rehab Centers

  • Research Institutes

  • Others


Cardiopulmonary Disease Diagnostics and Treatment Market, by Region


Americas



  • North America

  • US

  • Canada

  • South America


Europe



  • Western Europe

  • Germany

  • France

  • Italy

  • Spain

  • UK

  • Rest of Western Europe

  • Eastern Europe


Asia-Pacific



  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Rest of Asia-Pacific


Middle East & Africa



  • Middle East

  • Africa


Intended Audience



  • Governmental Agency

  • Educational Organizations

  • Medical Device Manufacturers

  • Research Institutes and Academic Centers

  • Market Research and Consulting



Frequently Asked Questions (FAQ) :


The inclusion of advanced technologies would ensure better growth for Cardiopulmonary Disease Diagnostics and Treatment Market.

The high cost of the treatment and strict regulations on pharmaceuticals can bog down the market.

Disease types included in Cardiopulmonary Disease Diagnostics and Treatment Market are cardiovascular and respiratory.

Diagnosis and treatment are types mentioned for the Cardiopulmonary Disease Diagnostics and Treatment Market.

The segment includes clinics, diagnostic centers, hospitals, research institutes, specialty clinics, and rehab centers, and others.

Table of Contents:

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Cardiopulmonary Disease Diagnostics and Treatment Market, by Disease Type

6.1 Introduction

6.2 Cardiovascular diseases

6.2.1 Coronary artery disease

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

6.2.2 Angina pectoris

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

6.2.3 Myocardial infraction

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

6.2.4 Dysrhythmia

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

6.2.5 Hypertension

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

6.2.6 Others

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

6.3 Respiratory diseases

6.3.1 Influenza

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

6.3.2 Asthma

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

6.3.3 Bronchitis

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

6.3.4 Emphysema

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

6.3.5 Cystic fibrosis

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

6.3.6 Others

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

Chapter 7. Global Cardiopulmonary Disease Diagnostics and Treatment Market, by Type

7.1 Introduction

7.2 Diagnostics

7.2.1 Electrocardiogram (ECG)

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.2.2 Holter monitoring

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.2.3 Echocardiogram

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.2.4 Stress test

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.2.5 Cardiac catheterization

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.2.6 Cardiac computerized tomography (CT) scan

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.2.7 Cardiac magnetic resonance imaging (MRI)

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.2.8 Single-photon emission computed tomography (SPECT)

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.2.9 Stress blood pressure monitors

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.2.10 Pulse oximeters

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.2.10 Spirometry

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.3 Treatment

7.3.1 Medication

7.3.1.1 Angiotensin-converting enzyme (ACE) inhibitors

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.3.1.2 Angiotensin II receptor blockers (ARBS)

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.3.1.3 Anticoagulants

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.3.1.4 Antiplatelet agents

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.3.1.5 Others

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

Chapter 8. Global Cardiopulmonary Disease Diagnostics and Treatment Market, by End-Users

8.1 Introduction

8.2 Hospitals

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

8.3 Clinics

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

8.4 Diagnostic centers

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

8.5 Specialty Clinics and Rehab Centers

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

8.6 Research Institutes

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

8.7 Others

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

Chapter 9. Global Cardiopulmonary Disease Diagnostics and Treatment, by Region

9.1 Introduction

9.2 Americas

9.2.1 North America

9.2.1.1 US

9.2.1.2 Canada

9.2.2 South America

9.3 Europe

9.3.1 Western Europe

9.3.1.1 Germany

9.3.1.2 France

9.3.1.3 Italy

9.3.1.4 Spain

9.3.1.5 UK

9.3.1.6 Rest of Western Europe

9.3.2 Eastern Europe

9.4 Asia-Pacific

9.4.1 Japan

9.4.2 China

9.4.3 India

9.4.4 Australia

9.4.5 South Korea

9.4.6 Rest of Asia-Pacific

9.5 Middle East & Africa

9.5.1 Middle East

9.5.2 Africa

Chapter 10. Company Landscape

10.1 Introduction

10.2 Market Share Analysis

10.3 Key Development & Strategies

Chapter 11. Company Profiles

11.1 Cardinal Health

11.1.1 Company Overview

11.1.2 Type Overview

11.1.3 Financials Overview

11.1.4 Key Developments

11.1.5 SWOT Analysis

11.2 Cosmed Medical

11.2.1 Company Overview

11.2.2 Type Overview

11.2.3 Financial Overview

11.2.4 Key Developments

11.2.5 SWOT Analysis

11.3 GE Healthcare

11.3.1 Company Overview

11.3.2 Type Overview

11.3.3 Financial Overview

11.3.4 Key Development

11.3.5 SWOT Analysis

11.4 Halma plc.

11.4.1 Company Overview

11.4.2 Technology/Business Segment Overview

11.4.3 Financial Overview

11.4.4 Key Development

11.4.5 SWOT Analysis

11.5 Hill-Rom Holdings, Inc.

11.5.1 Company Overview

11.5.2 Type Overview

11.5.3 Financial overview

11.5.4 Key Developments

11.5.5 SWOT Analysis

11.6 Koninklijke Philips N.V.

11.6.1 Company Overview

11.6.2 Type Overview

11.6.3 Financial Overview

11.6.4 Key Developments

11.6.5 SWOT Analysis

11.7 MGC Diagnostics Corporation

11.7.1 Overview

11.7.2 Type Overview

11.7.3 Financial Overview

11.7.4 Key Developments

11.7.5 SWOT Analysis

11.8 NIHON KOHDEN CORPORATION

11.8.1 Overview

11.8.2 Type/ Technology Overview

11.8.3 Financials

11.8.4 Key Developments

11.8.5 SWOT Analysis

11.9 Schiller AG

11.9.1 Overview

11.9.2 Type Overview

11.9.3 Financials

11.9.4 Key Developments

11.9.5 SWOT Analysis

11.9 Masimo Corporation

11.9.1 Overview

11.9.2 Type Overview

11.9.3 Financials

11.9.4 Key Developments

11.9.5 SWOT Analysis

11.11 Vyaire Medical Inc.

11.11.1 Overview

11.11.2 Type Overview

11.11.3 Financials

11.11.4 Key Developments

11.11.5 SWOT Analysis

Chapter 12 MRFR Conclusion

12.1 Key Findings

12.1.1 From CEO’s Viewpoint

12.1.2 Unmet Needs of the Market

12.2 Key Companies to Watch

12.3 Predictions for the Cardiopulmonary Disease Diagnostics and Treatment Industry

Chapter 13. Appendix

LIST OF TABLES

Table 1 Global Cardiopulmonary Disease Diagnostics and Treatment Market Synopsis, 2020–2027

Table 2 Global Cardiopulmonary Disease Diagnostics and Treatment Market Estimates and Forecast, 2020–2027 (USD Million)

Table 3 Global Cardiopulmonary Disease Diagnostics and Treatment Market, by Region, 2020–2027 (USD Million)

Table 4 Global Cardiopulmonary Disease Diagnostics and Treatment Market, by Type, 2020–2027 (USD Million)

Table 5 Global Cardiopulmonary Disease Diagnostics and Treatment Market, by Disease type, 2020–2027 (USD Million)

Table 6 Global Cardiopulmonary Disease Diagnostics and Treatment Market, by End-users, 2020–2027 (USD Million)

Table 7 North America: Cardiopulmonary Disease Diagnostics and Treatment Market, by Type, 2020–2027 (USD

Million)

Table 8 North America: Cardiopulmonary Disease Diagnostics and Treatment Market, by Disease type, 2020–2027 (USD

Million)

Table 9 North America: Cardiopulmonary Disease Diagnostics and Treatment Market, by End-users, 2020–2027 (USD Million)

Table 10 US: Cardiopulmonary Disease Diagnostics and Treatment Market, by Type, 2020–2027 (USD Million)

Table 11 US: Cardiopulmonary Disease Diagnostics and Treatment Market, by Disease type, 2020–2027 (USD Million)

Table 12 US: Cardiopulmonary Disease Diagnostics and Treatment Market, by End-users, 2020–2027 (USD Million)

Table 13 Canada: Cardiopulmonary Disease Diagnostics and Treatment Market, by Type, 2020–2027 (USD Million)

Table 14 Canada: Cardiopulmonary Disease Diagnostics and Treatment Market, by Disease type, 2020–2027 (USD Million)

Table 15 Canada Cardiopulmonary Disease Diagnostics and Treatment Market, by End-users, 2020–2027 (USD Million)

Table 16 South America: Cardiopulmonary Disease Diagnostics and Treatment Market, by Type, 2020–2027 (USD

Million)

Table 17 South America: Cardiopulmonary Disease Diagnostics and Treatment Market, by Disease type, 2020–2027 (USD

Million)

Table 18 South America: Cardiopulmonary Disease Diagnostics and Treatment Market, by End-users, 2020–2027 (USD Million)

Table 19 Europe: Cardiopulmonary Disease Diagnostics and Treatment Market, by Type, 2020–2027 (USD Million)

Table 20 Europe: Cardiopulmonary Disease Diagnostics and Treatment Market, by Disease type, 2020–2027 (USD Million)

Table 21 Europe: Cardiopulmonary Disease Diagnostics and Treatment Market, by End-users, 2020–2027 (USD Million)

Table 22 Western Europe: Cardiopulmonary Disease Diagnostics and Treatment Market, by Type, 2020–2027 (USD

Million)

Table 23 Western Europe: Cardiopulmonary Disease Diagnostics and Treatment Market, by Disease type, 2020–2027 (USD

Million)

Table 24 Western Europe: Cardiopulmonary Disease Diagnostics and Treatment Market, by End-users, 2020–2027 (USD Million)

Table 25 Eastern Europe Cardiopulmonary Disease Diagnostics and Treatment Market, by Type, 2020–2027 (USD

Million)

Table 26 Eastern Europe: Cardiopulmonary Disease Diagnostics and Treatment Market, by Disease type, 2020–2027 (USD

Million)

Table 27 Eastern Europe: Cardiopulmonary Disease Diagnostics and Treatment Market, by End-users, 2020–2027 (USD Million)

Table 28 Asia-Pacific: Cardiopulmonary Disease Diagnostics and Treatment Market, by Type, 2020–2027 (USD

Million)

Table 29 Asia-Pacific: Cardiopulmonary Disease Diagnostics and Treatment Market, by Disease type, 2020–2027 (USD

Million)

Table 30 Asia-Pacific: Cardiopulmonary Disease Diagnostics and Treatment Market, by End-users, 2020–2027 (USD Million)

Table 31 Middle East & Africa: Cardiopulmonary Disease Diagnostics and Treatment Market, by Type, 2020–2027

(USD Million)

Table 32 Middle East & Africa: Cardiopulmonary Disease Diagnostics and Treatment Market, by Disease type, 2020–2027

(USD Million)

Table 33 Middle East & Africa Cardiopulmonary Disease Diagnostics and Treatment Market, by End-users, 2020–2027 (USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Global Cardiopulmonary Disease Diagnostics and Treatment Market

Figure 3 Segmentation Market Dynamics for Global Cardiopulmonary Disease Diagnostics and Treatment Market

Figure 4 Global Cardiopulmonary Disease Diagnostics and Treatment Market Share, by Type, 2020

Figure 5 Global Cardiopulmonary Disease Diagnostics and Treatment Market Share, by Disease type, 2020

Figure 6 Global Cardiopulmonary Disease Diagnostics and Treatment Market, by End-users, 2020–2027 (USD Million)

Figure 7 Global Cardiopulmonary Disease Diagnostics and Treatment Market Share, by Region, 2020

Figure 8 North America: Cardiopulmonary Disease Diagnostics and Treatment Market Share, by Country, 2020

Figure 9 Europe: Cardiopulmonary Disease Diagnostics and Treatment Market Share, by Country, 2020

Figure 10 Asia-Pacific: Cardiopulmonary Disease Diagnostics and Treatment Market Share, by Country, 2020

Figure 11 Middle East & Africa: Cardiopulmonary Disease Diagnostics and Treatment Market Share, by Country, 2020

Figure 12 Global Cardiopulmonary Disease Diagnostics and Treatment Market: Company Share Analysis, 2020 (%)

Figure 13 Cardinal Health: Key Financials

Figure 14 Cardinal Health: Segmental Revenue

Figure 15 Cardinal Health: Geographical Revenue

Figure 16 Cosmed Medical: Key Financials

Figure 17 Cosmed Medical: Segmental Revenue

Figure 18 Cosmed Medical: Geographical Revenue

Figure 19 GE Healthcare: Key Financials

Figure 20 GE Healthcare: Segmental Revenue

Figure 21 GE Healthcare: Geographical Revenue

Figure 22 Halma plc: Key Financials

Figure 23 Halma plc: Segmental Revenue

Figure 24 Halma plc: Geographical Revenue

Figure 25 Hill-Rom Holdings, Inc.: Key Financials

Figure 26 Hill-Rom Holdings, Inc.: Segmental Revenue

Figure 27 Hill-Rom Holdings, Inc.: Geographical Revenue

Figure 28 Koninklijke Philips N.V.: Key Financials

Figure 29 Koninklijke Philips N.V: Segmental Revenue

Figure 30 Koninklijke Philips N.V.: Geographical Revenue

Figure 31 MGC Diagnostics Corporation: Key Financials

Figure 32 MGC Diagnostics Corporation: Segmental Revenue

Figure 33 MGC Diagnostics Corporation: Geographical Revenue

Figure 34 NIHON KOHDEN CORPORATION: Key Financials

Figure 35 NIHON KOHDEN CORPORATION: Segmental Revenue

Figure 36 NIHON KOHDEN CORPORATION: Geographical Revenue

Figure 37 Schiller AG: Key Financials

Figure 38 Schiller AG Segmental Revenue

Figure 39 Schiller AG: Geographical Revenue

Figure 40 Masimo Corporation: Key Financials

Figure 41 Masimo Corporation: Segmental Revenue

Figure 42 Masimo Corporation: Geographical Revenue

Figure 43 Vyaire Medical Inc.: Key Financials

Figure 44 Vyaire Medical Inc.: Segmental Revenue

Figure 45 Vyaire Medical Inc.: Geographical Revenue